Search Results for

SGN35-027

Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Continue Reading »

---

C2321001

PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Continue Reading »

---

EA4181

A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma

Continue Reading »

---

A051701

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

Continue Reading »

---

S1826

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

Continue Reading »

---

TG-1501-101

A Phase 1 Study of TG-1501 in Subjects With Relapsed or Refractory Lymphoma

Continue Reading »

---

E4412

Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Continue Reading »

---

S1608

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

Continue Reading »

---

CA209-655

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Continue Reading »

---

Search Again

• All Trial Categories Anal  (3) Bladder/Urinary Tract Cancer  (8)    Adjuvant  (1)    Metastatic  (2)    Neoadjuvant  (4) Brain  (7)    Glioblastoma Multiforme (GBM)  (3)    Other Brain Tumors  (3) Breast  (17)    1st Line Metastatic Breast, Metastasis at Presentation or Progression of earlier Disease  (5)    2nd Line Metastatic Breast, Progressive Disease Following 1st Line Therapy  (1)    Breast Cancer Adjuvant  (5)    Breast Cancer Neoadjuvant  (1)    DCIS/LCIS  (1) Cancer Control/Symptom Management  (22) Carcinoid Tumors  (2) Colorectal Cancer  (10)    Metastatic  (4)    Rectal Neoadjuvant  (1) Esophageal Cancer  (2) Gall Bladder/ Biliary Tract Cancer  (1) Gastric Cancer  (2)    Metastaic Gastric Cancer  (1) Head/Neck Cancer  (4)    Resectable Oral Cavity Cancer  (1)       Primary Chemoradiation Regimens  (1) Leukemia  (9)    Acute Myeloid Leukemia (AML)  (1)    B-Cell Chromic Lymphocytic Leukemia (CLL) / Small Ly  (5) Liver/Hepatocellular Carcinoma  (1) Lung Cancer  (24)    Non-Small Cell Lung Cancer  (19)       1st Line Metastatic, Stage3b with Maligned Effusion or Stage 4 Disease at Presentation or Recurrence  (3)       2nd Line Metastatic, Stage 4 Patients with Progressive Disease  (4)       Adjuvant Treatment for Resected NSCLC  (4)    Small Cell Lung Cancer  (5)       Extensive Stage SCLC  (2) Lymphoma  (9)    Non-Hodgkin’s Lymphoma  (4)       Diffuse Large B-Cell Lymphoma  (1)       Follicular Lymphoma  (2)          Relapsed/Refractory  (2) MATCH Trial  (1) MDS  (3) Melanoma  (7)    Metastatic  (3) Merkel Cell Carcinoma  (1) Multiple Myeloma  (2) Pancreatic  (6)    Metastatic Disease  (4) Prostate  (9) Renal Cell/Kidney Cancer  (6)    Locally Advanced/Metastatic  (4) Sarcoma  (2) Small Bowel  (1)